The NHLBI-Sponsored Consortium for preclinicAl assESsment of cARdioprotective Therapies (CAESAR) A New Paradigm for Rigorous, Accurate, and Reproducible …
Rationale: Despite 4 decades of intense effort and substantial financial investment, the
cardioprotection field has failed to deliver a single drug that effectively reduces myocardial …
cardioprotection field has failed to deliver a single drug that effectively reduces myocardial …
The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible …
SP Jones, XL Tang, Y Guo… - Circulation …, 2015 - pubmed.ncbi.nlm.nih.gov
Rationale Despite 4 decades of intense effort and substantial financial investment, the
cardioprotection field has failed to deliver a single drug that effectively reduces myocardial …
cardioprotection field has failed to deliver a single drug that effectively reduces myocardial …
The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible …
SP Jones, XL Tang, Y Guo, C Steenbergen… - Circulation …, 2014 - europepmc.org
Objective To develop a multicenter, randomized, controlled, clinical trial-like infrastructure to
conduct rigorous and reproducible preclinical evaluation of cardioprotective therapies …
conduct rigorous and reproducible preclinical evaluation of cardioprotective therapies …
The NHLBI-Sponsored Consortium for preclinicAl assESsment of cARdioprotective Therapies (CAESAR): A new paradigm for rigorous, accurate, and reproducible …
SP Jones, XL Tang, Y Guo… - Circulation …, 2015 - pure.johnshopkins.edu
Rationale: Despite 4 decades of intense effort and substantial financial investment, the
cardioprotection field has failed to deliver a single drug that effectively reduces myocardial …
cardioprotection field has failed to deliver a single drug that effectively reduces myocardial …
The NHLBI-Sponsored Consortium for preclinicAl assESsment of cARdioprotective Therapies (CAESAR)
SP Jones, XL Tang, Y Guo, C Steenbergen, DJ Lefer… - 2014 - Am Heart Assoc
Objective: To develop a multicenter, randomized, controlled, clinical trial-like infrastructure to
conduct rigorous and reproducible preclinical evaluation of cardioprotective therapies …
conduct rigorous and reproducible preclinical evaluation of cardioprotective therapies …
The NHLBI-Sponsored Consortium for preclinicAl assESsment of cARdioprotective Therapies (CAESAR)
SP Jones, XL Tang, Y Guo, C Steenbergen… - Circulation …, 2015 - ingentaconnect.com
Rationale: Despite 4 decades of intense effort and substantial financial investment, the
cardioprotection field has failed to deliver a single drug that effectively reduces myocardial …
cardioprotection field has failed to deliver a single drug that effectively reduces myocardial …
The NHLBI-Sponsored Consortium for preclinicAl assESsment of cARdioprotective Therapies (CAESAR) A New Paradigm for Rigorous, Accurate, and Reproducible …
SP Jones, XL Tang, Y Guo, C Steenbergen… - Circulation …, 2015 - hero.epa.gov
Rationale: Despite 4 decades of intense effort and substantial financial investment, the
cardioprotection field has failed to deliver a single drug that effectively reduces myocardial …
cardioprotection field has failed to deliver a single drug that effectively reduces myocardial …
[HTML][HTML] The NHLBI-Sponsored Consortium for preclinicAl assESsment of cARdioprotective Therapies (CAESAR): A New Paradigm for Rigorous, Accurate, and …
SP Jones, XL Tang, Y Guo, C Steenbergen… - Circulation …, 2015 - ncbi.nlm.nih.gov
Objective To develop a multicenter randomized controlled trial (RCT)-like infrastructure to
conduct rigorous and reproducible preclinical evaluation of cardioprotective therapies …
conduct rigorous and reproducible preclinical evaluation of cardioprotective therapies …
The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible …
SP Jones, XL Tang, Y Guo, C Steenbergen… - Circulation …, 2014 - europepmc.org
Objective To develop a multicenter, randomized, controlled, clinical trial-like infrastructure to
conduct rigorous and reproducible preclinical evaluation of cardioprotective therapies …
conduct rigorous and reproducible preclinical evaluation of cardioprotective therapies …